FDA Pediatric/Counterterrorism Office Selects New Director
This article was originally published in The Pink Sheet Daily
Executive Summary
The Office of Counter-Terrorism and Pediatric Drug Development selects Deputy Director Rosemary Roberts to head office. OCTAP Director Dianne Murphy will dedicate herself full-time to her other position as pediatric therapeutics director.
You may also be interested in...
Supplemental Filings: Ycanth Approved For Molluscum; CDER Counter-Terrorism Head Retires; 5 Benzodiazepines Added To Schedule I
The fourth review cycle is the charm for Verrica's cantharidin topical solution; Rosemary Roberts, head of CDER's Counter-Terrorism and Emergency Coordination Staff, retires after 35 years at the FDA; DEA deems five designer benzodiazepines with no currently accepted medical use in the US as Schedule I controlled substances.
FDA Announces Pediatric Personnel Changes
Office of Counter-Terrorism & Pediatric Drug Development Director Dianne Murphy, MD, will leave that position in September to dedicate herself full-time to her other position in the Office of the Commissioner as office of pediatric therapeutics director
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.